Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + glasdegib
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
Azacitidine + glasdegib is an investigational combination therapy consisting of azacitidine, a pyrimidine nucleoside analogue with DNA hypomethylating and cytotoxic activity, and glasdegib, an oral small molecule inhibitor of the Hedgehog signaling pathway through inhibition of Smoothened. This combination is being studied for the treatment of adult patients with previously untreated acute myeloid leukemia (AML), particularly in those who are not candidates for intensive induction chemotherapy. Azacitidine inhibits DNA methyltransferase, leading to impaired DNA methylation and disruption of RNA and DNA synthesis. Glasdegib targets the Hedgehog pathway, which plays a role in leukemic stem cell maintenance and the pathogenesis of AML, aiming to suppress leukemic stem cells and prevent relapse[1][2][3][4][5][6].
- Other names
- glasdegib plus azacitidine
02
Targets
DNMT (DNA methyltransferase)SMO (Smoothened)
Beyond the preview
Go deeper on azacitidine + glasdegib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + glasdegib.